The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Treating Ductal Carcinoma In Situ with Surgery, Radiotherapy Offers Better Protection Than Surgery Alone
Although only a proportion of DCIS cases will progress into invasive cancer, the treatments available for DCIS are similar to treatments for invasive breast cancers.
According to the study authors, previous small studies suggested that women taking statins may have less heart muscle damage from these types of chemotherapy, yet the exact mechanisms of how statins protect against the cardiac cell damage remains unknown.
This study points to the potential for using CAR T-cell therapy effectively against solid tumors, as well, according to the authors.
The FDA has granted a fast track designation to an investigational antibody-drug conjugate for use as a monotherapy in the treatment of patients with advanced or metastatic HER2-positive breast cancer.
Symposium speakers discussed how CDK4/6 inhibitors are game changers in treatment of HR+/HER2- advanced breast cancer.
Targeting screening to high-risk groups who are less compliant with recommendations could be more effective than general age-based recommendations.
Updated Study Data Shows Oral Paclitaxel and Encequidar Is Beneficial in Patients with Metastatic Breast Cancer
Updated phase 3 progression-free survival and overall survival data demonstrated clinical benefits in efficacy and tolerability of oral paclitaxel and encequidar versus intravenous paclitaxel in patients with metastatic breast cancer.
FDA approves margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens.
Financial toxicity can lead to worse long-term outcomes and psychological distress among patients with breast cancer.
Study shows the mortality rate among breast cancer survivors is lower among those who received fertility preservation.
Study: Omitting Radiation Therapy After Breast Conserving Surgery May Not Impact 10-Year Survival Rates
Although postoperative radiation therapy affected the risk of local recurrence of breast cancer, it did not significantly impact certain other clinical outcomes, including distant metastasis and recurrence in the opposite breast.
The higher risk of delivery and fetal complications suggests that physicians should more closely monitor pregnant breast cancer survivors.